

IN THIS ISSUE

PUBLICATIONS IN THE COCHRANE LIBRARY (THE CLIB). ISSUE 11 OF 2015 THROUGH ISSUE 2 OF 2016

PAST EVENTS


- **37TH CHBG MEETING AND EXHIBITION STAND DURING THE LIVER@ MEETING, SAN FRANCISCO, CA, USA. NOVEMBER 13 TO NOVEMBER 17, 2015**

FUTURE EVENTS

- **38TH CHBG MEETING DURING THE LIVER@ CONGRESS™, BARCELONA, SPAIN. JOINT EASL -- CHBG WORKSHOP PROGRAMME 13 APRIL, 2016**

VISITORS

FOR AUTHORS



Weight-reducing diets for people with elevated blood pressure

Compared to the general population, people with high blood pressure have a higher risk of death and complications such as heart attack or stroke. Dietary interventions to lower body weight are commonly recommended as a first therapeutic step for overweight people with high blood pressures, based on the association of increased weight and increased blood ...

Updated • COCHRANE EVIDENCE • Published 2 Mar 2016

Long-term effects of weight-reducing drugs in people with elevated blood pressure

Doctors often recommend that people who are overweight or obese with elevated blood pressure lose weight, which may include taking anti-obesity drugs to assist in weight and blood pressure reduction. Two active ingredients (rimonabant and sibutramine) were withdrawn from the market in 2009 and 2010, respectively. Current guidelines for the pharmacological ...

Items • COCHRANE EVIDENCE • Published 2 Mar 2016

Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease

Background Heavy alcohol consumption causes alcoholic liver disease and may lead to a number of other concomitant diseases. Alcohol may damage the function of body organs and can cause cancer. Liver damage due to excessive alcohol consumption is usually presented as fatty liver (build-up of fats in the liver), steatohepatitis (inflammation of the liver ...

NEWS • Published 1 Mar 2016

Cochrane announces new partnership with the Joanna Briggs Institute

Cochrane and the Joanna Briggs Institute (JBI), a research and development centre within the Faculty of Health Sciences at the University of Adelaide, South Australia, are delighted to announce their official partnership aimed at improving the knowledge b ...

NEWS • Published 1 Mar 2016

Cochrane seeks Team Administrator - London, UK

Specifications: Full time or part-time/job share position Salary: £18,000- 22,000 (dependent on experience) Location: London

The numbering is a continuation from Vol. 19, Issue 2, 2015.

PUBLICATIONS IN THE COCHRANE LIBRARY (THE CLIB). ISSUE 11 OF 2015 THROUGH ISSUE 2 OF 2016

NEW REVIEWS

- 188. Antibiotic prophylaxis for surgical site infection in people undergoing liver transplantation. Almeida RAMB, Hasimoto CN, Kim A, Hasimoto EN, El Dib R.
- 189. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients. Fairfield C, Penninga L, Powell J, Harrison EM, Wigmore SJ.
- 190. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Abdel-Rahman OM, Elsayed Z.

UPDATED REVIEWS

None.

NEW PROTOCOLS

- 316. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Abdel-Rahman OM, Elsayed Z.
- 317. Interferon alpha versus any other drug for chronic hepatitis D. Abbas Z, Ali SS, Shazi L.
- 318. Banding ligation versus sclerotherapy for primary prophylaxis of oesophageal varices in children. Gana JC, Cifuentes LI, Cerda J, Villarroel del Pino LA, Peña A, Torres-Robles R.
- 319. Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage. Brand M, Prodehl L.

320. Beta-blockers versus placebo or no intervention for primary prophylaxis of oesophageal varices in children. Gana JC, Cifuentes LI, Cerda J, Villarroel del Pino LA, Peña A, Torres-Robles R.

321. Forns index and 'FIB4' for staging of fibrosis in adults with chronic hepatitis C. Kalafateli M, Gurusamy KS, Noel-Storr AH, Burroughs AK, Tsochatzis E.

322. S-adenosyl-L-methionine for people with alcoholic liver disease. Pavlov CS, Casazza G, Nikolova D, Tikhonov I, Tsochatzis E, Gluud C.

323. Adefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infection. Mok S, Mohan S, Hunter KM, Wang YR, Judge TA.

324. Bile acid derivatives for people with primary biliary cholangitis. Ecker J, Lammert F, Gluud LL, Stokes CS.

325. Bile acid derivatives for people with primary sclerosing cholangitis. Ecker J, Lammert F, Gluud LL, Stokes CS.

326. Adefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infection. Mok S, Mohan S, Hunter KM, Wang YR, Judge TA.

NEW REGISTERED TITLES

498. Targeted drug therapy for advanced biliary tract cancer. Chindaprasirt J, Wirasorn K, Sookprasert A, Ngamjarus C, Lumbiganon P.

499. Selective versus routine intraoperative cholangiography during cholecystectomy. Kleinubing D, Riera R, Matos D, Linhares Mmoura.

500. Postoperative adjuvant chemotherapy for cholangiocarcinoma. Luvira V, Pugkhem A, Satitkarnmanee E, Kietpeerakool C, Lumbiganon P, Kamsa-ard S, Pattanittum P.

501. Endoscopic versus surgical palliation for malignant distal bile duct obstruction. Lean LL, Samuel M, Koh CJ, Ibrahim I, Choong SK.

502. Transabdominal ultrasound or endoscopic ultrasound for diagnosis of gallbladder polyps. Wennmacker SZ., Lamberts M, Drenth JPH, Gurusamy KS, van Laarhoven CJHM.

503. Vasoactive drugs for hepatorenal syndrome (network meta-analysis). Allegretti A, Gluud LL.

504. Transarterial (chemo)embolisation versus chemotherapy for liver metastasis. Bala MM, Riemsma RP, Wolff R, Hetnal M, Mitus J, Kukielka A, Kleijnen J.

PAST EVENTS

37TH CHBG MEETING AND EXHIBITION STAND DURING THE LIVER® MEETING, SAN FRANCISCO, CA, USA. NOVEMBER 13 TO NOVEMBER 17, 2015

We thank all people who attended The CHBG meeting November 16th, 2015 and visited The CHBG exhibition stand.

FUTURE EVENTS

38TH CHBG MEETING DURING THE LIVER® CONGRESS™, BARCELONA, SPAIN.

The International Liver Congress™ 2016 will take place from 13 to 17 April, 2016 at the Fira Barcelona Gran Via, Barcelona, Spain.

A joint **workshop, EASL – CHBG**, will be run Wednesday **13 April 2016**, from **08:00 to 11:00 in Hall 8.0-F8 of Fira Barcelona.**

Description:

Based on four systematic reviews of interventions for different liver conditions (chronic hepatitis C; hospitalised liver patients; primary biliary cholangitis; and hepatic encephalopathy) the harms and benefits of different interventions for these conditions will be evaluated in Cochrane Hepato-Biliary systematic reviews with meta-analysis, Trial Sequential Analysis, and network meta-analysis. Furthermore, non-invasive diagnostic tests for oesophageal varices will be assessed in a Cochrane Hepato-Biliary diagnostic accuracy test review. The learning objectives are to understand the powers and weaknesses of systematic reviewing outperforming even large single randomised clinical trials.

Chairs: Christian Gluud (DK) (CHBG), Cecilia Rodrigues (PT) (EASL).

Presentations:**Meeting location: Hall 8.0-E8**

08:00 - 08:05 Welcome. Speakers: Christian Gluud (DK) (CHBG), Cecilia Rodrigues (PT) (EASL).

08:05 - 08:35 Direct acting antivirals: do they work beyond sustained virological response in chronic hepatitis C patients? Speaker: Ronald L. Koretz (US).

08:35 - 09:05 The effects of nutrition to hospitalized liver patients – a systematic review. Speaker: Joshua Rose-Hansen Feinberg (DK).

09:05 - 09:30 Ursodeoxycholic acid for primary biliary cirrhosis – a systematic review. Speaker: Jelena S. Nincevic (Republic of Serbia).

09:30 – 10:00 **Coffee break.**

10:00 - 10:30 Non-invasive diagnostic tests for oesophageal varices – a systematic review. Speaker: Agostino Colli (I).

10:30 - 11:00 Nonabsorbable disaccharides for hepatic encephalopathy – a systematic review. Speaker: Lise Lotte Gluud (DK).

For further information, please visit

<http://ilc-congress.eu/programme-highlights/joint-workshops/>

The meeting is free for all attendants. We will be most happy to see you there.

The CHBG will also have an **exhibition stand**. It is number **2400A**. Come and visit us.

More details may follow on The CHBG website [hbg.cochrane.org].

VISITORS

Last year, **Cristina Manzotti**, from Italy, paid the Editorial Team Office of The CHBG in Copenhagen, Denmark a three-months visit to work on the

diagnostic test accuracy review 'Total serum bile acids and/or serum bile acid profile for the diagnosis of intrahepatic cholestasis of pregnancy'. During this period of time, **Tea Stimac**, a co-author from Croatia, came to work for five days with Cristina Manzotti on the review (16 - 21 November 2015).

Chavdar S Pavlov, from Russia, visited the Editorial Team Office of The CHBG in Copenhagen, Denmark from 1 to 15 of February, 2016. Chavdar Pavlov and co-authors continued their work through Skype on Cochrane systematic reviews. As a result, the Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease review was finalised and published on The Cochrane Library. Chavdar and co-authors also worked on an invited editorial regarding the already published Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease review published also in *Alimentary Pharmacology & Therapeutics*.

Daria Varganova, from Russia, visited the Editorial Team office of the CHBG in Copenhagen, Denmark, during the same time as Chavdar S Pavlov. Her two-week visit was sponsored by a Mentorship programme, initiated by EASL in 2012. The programme aims at enhancing scientific exchange and personal development relationships across European countries.

Daria Varganova was taught in Cochrane review methodology including how to develop a Cochrane protocol for a systematic review, how to critically read and comment on a protocol, and how to develop a protocol into a systematic review. The review process included knowledge on how to select randomised clinical trials from a search performed in a number of literature databases, how to find out which trials fulfill the inclusion criteria of a protocol, how to identify multiple

publications and critically read and account for missing participants or errors in the publications reporting on the trials.

The ongoing review 'Glucocorticosteroids for people with alcoholic hepatitis' (authored by Chavdar S Pavlov and colleagues) was used for Daria Varganova's training. In addition, some time was spent on how to assess risk of bias of trials following definitions of risk of bias domains, how to build up comparisons in the Review Manager software (used for production of Cochrane reviews), how to enter data for meta-analyses with fixed-effect or random-effects method, and how to define and perform Trial Sequential Analysis to control for random errors in trials.

FOR AUTHORS

The Cochrane training webpage

<http://training.cochrane.org/> provides an excellent opportunity for Cochrane authors to learn about Cochrane systematic review preparation. We strongly encourage people to use the material on it. It is accessible through your Archie log in information.

Task Exchange connects people who need help with their Cochrane reviews with people who have the time and expertise to help.

Check it out at taskexchange.cochrane.org and see whether you want to post a task, can help someone else, or do both.

The Cochrane Hepato-Biliary Group (The CHBG) Newsletter is written, edited, and published in electronic and paper format by Dimitrinka Nikolova and Christian Gluud at The CHBG Editorial Office in Copenhagen, Denmark.

It is issued twice a year and it is also distributed for free world-wide to all people on The CHBG members list who have contributed, are contributing, or have shown interest in the work of The CHBG or in this CHBG Newsletter.

The purpose with The CHBG Newsletter is to inform its readers about activities of The CHBG.

**Editorial CHBG staff at
The CHBG Editorial Office**

**Christian Gluud, Co-ordinating & Criticism Editor, E-mail: cgluud@ctu.dk;
Dimitrinka Nikolova, Managing Editor, E-mail: dimitrinka.nikolova@ctu.dk;
Sarah Louise Klingenberg, Trials Search Co-ordinator, E-mail: slk@ctu.dk**

Postal address

**The Cochrane Hepato-Biliary Group/The Copenhagen Trial Unit,
Centre for Clinical Intervention Research
Department 7812, Rigshospitalet, Blegdamsvej 9, Copenhagen Ø, DK-2100
Tel. +45 3545 7169 or +45 3545 7175
Fax +45 3545 7101
Web site: hbg.cochrane.org**

Visiting address

Department 7812, Tagensvej 22, 2nd floor, Copenhagen N, DK-2200

